On : 01 july 2025
• Global OTC Anti-Infective Products market size was valued at USD 13,000 million in 2024 and is projected to grow from USD 13,481 million in 2025 to USD 16,640 million by 2032, exhibiting a CAGR of 3.7% during the forecast period.
Email: help@intelmarketresearch.com +91 9169164321
• The global Over-the-Counter (OTC) Anti-Infective Products market is witnessing steady growth driven by rising consumer awareness regarding self-medication, increasing prevalence of minor infections, and easy accessibility of non-prescription drugs. These products, which include antibacterial, antiviral, antifungal, and antiseptic agents, are commonly used to treat conditions like colds, flu, skin infections, and minor wounds without the need for a healthcare professional's prescription. The growing demand for convenience, coupled with the expansion of pharmacy chains and e-commerce platforms, is fueling market expansion. Moreover, the aging population and frequent travel are contributing to higher incidences of infections, further supporting product adoption. Regulatory support for safe OTC switches and ongoing innovation in formulations, such as combination products and natural/herbal alternatives, are also propelling the market forward. However, concerns regarding inappropriate use, resistance development, and limited product scope compared to prescription alternatives remain key challenges.
•Antibacterial
•Antiviral
•Antiseptics
•Subtypes: Alcohol-based, iodine-based, and others
•Others
• Skin Infections
• Respiratory Infections
• Eye Infections
• Ear Infections
• Fungal Infections (e.g., athlete’s foot, ringworm)
• Cold Sores and Herpes
• Oral Thrush
Email: help@intelmarketresearch.com
•Bayer AG (Germany)
•Abbott Laboratories (U.S.)
•Ferring Pharmaceuticals (Switzerland)
•Xianju Pharma (China)
•AstraZeneca (UK)
•Merck & Co. (U.S.)
•Takeda Pharmaceutical (Japan)
•Theramex (UK)
Email: help@intelmarketresearch.com +91 9169164321
